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Abstract
Background: There is current controversy about the efficacy of smoking cessation interventions that are based on
information obtained by spirometry. The objective of this study is to evaluate the effectiveness in the primary care
setting of structured motivational intervention to achieve smoking cessation, compared with usual clinical practice.
Methods
Design: Multicentre randomized clinical trial with an intervention and a control group.
Setting: 12 primary care centres in the province of Tarragona (Spain).
Subjects of study: 600 current smokers aged between 35 and 70 years with a cumulative habit of more than 10
packs of cigarettes per year, attended in primary care for any reason and who did not meet any of the exclusion
criteria for the study, randomly assigned to structured intervention or standard clinical attention.
Intervention: Usual advice to quit smoking by a general practitioner as well as a 20-minute personalized visit to
provide detailed information about spirometry results, during which FEV1, FVC, FEF 25-75% and PEF measurements
were discussed and interpreted in terms of theoretical values. Additional information included the lung age index
(defined as the average age of a non-smoker with the same FEV1 as the study participant), comparing this with
the chronological age to illustrate the pulmonary deterioration that results from smoking.
Measurements: Spirometry during the initial visit. Structured interview questionnaire administered at the primary
care centre at the initial visit and at 12-month follow-up. Telephone follow-up interview at 6 months. At 12-month
follow-up, expired CO was measured in patients who claimed to have quit smoking.
Main variables: Smoking cessation at 12 months.
Analysis: Data will be analyzed on the basis of “intention to treat” and the unit of analysis will be the individual
smoker.
Expected results: Among active smokers treated in primary care we anticipate significantly higher smoking
cessation in the intervention group than in the control group.
Discussion: Application of a motivational intervention based on structured information about spirometry results,
improved abstinence rates among smokers seen in actual clinical practice conditions in primary care.
Trial registration: ClinicalTrial.gov, number NCT01194596.
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Smoking is the principal avoidable risk factor and etiologi-
cal cause of numerous pathologies, including respiratory
tract [1]. Smoking accelerates the physiological decline of
pulmonary volume usually attributable to age, and the
most susceptible subjects may develop chronic obstructive
pulmonary disease (COPD) [2]. The estimated absolute
risk of COPD for smokers is at least 25% [3]. The preva-
lence of COPD increases with age and is more frequent in
men, but this appears to be related to the cumulative effect
of other risk factors to which the individual has been
exposed during a lifetime [4]. Spirometry is considered the
standard test for the diagnosis and monitoring of COPD
[5,6]; nevertheless, it appears to be an inefficient screening
tool for the general population. Some institutions advise
against its systematic use in asymptomatic subjects for var-
ious reasons, not only cost-benefit considerations [7]. In
addition, the available evidence seems to indicate that the
information spirometry provides does not modify COPD
management in the early stages of disease [8], when quit-
ting a smoking habit is the most effective therapeutic
intervention and the only one that increases survival [1].
Therefore, early intervention is considered crucial.
From a therapeutic perspective, smoking is a chronic
disease of an addictive nature, with frequent relapses that
reflect the intensity of nicotine dependence. The available
data suggest that most smokers are interested in quitting
and that structured advice from health professionals with
whom they are in contact is an important motivating ele-
ment [9]. Therefore, interventions based on individual or
group counselling should be the first step in smoking ces-
sation, with the addition of pharmacological treatment
when educational strategies have not been effective [10].
In fact, the combination of advice and medication is more
likely to succeed than either approach in isolation. In
patients with COPD, a recent study indicates that rates of
abstinence increase as interventions are added, from 2.6%
with brief counselling to 12.3% when combined with drug
therapy [11]. However, while it is true that adding medica-
tion significantly improves abstinence, cessation efforts
often fail because of the lack of motivation of smokers
[12]. In an effort to improve success rates, spirometry was
advised as a motivational tool to reinforce the smoking
cessation message provided by counselling [13].
Some years ago, the Lung Health Study showed that
COPD could be detected early through the use of spiro-
metry and established the benefits of smoking cessation
for changing the natural history of the disease [14]. In
addition, the quit rate among participants included in
the intensive program was 21.7%, compared to 5.4%
among subjects in the standard program [15,16]. Bed-
narek et al. [17] have also published results obtained in
a cohort of 4494 smokers in Poland who received a
minimal intervention, placing their spirometry data on
the classic Fletcher-Peto graph [18]. After 1 year of fol-
low-up, the cessation rate was significantly higher in
patients with COPD than in subjects with normal spiro-
metry (16.3% vs 12.0%; P = 0.0003). Therefore, it is logi-
cal to assume that information about respiratory
function testing could also be helpful. However, these
results are from observational studies lacking sufficient
statistical power to support any recommendations, lead-
i n gs o m ea u t h o r st of i n dt h ee v i d e n c eo ft h em o t i -
vational merits of spirometry testing to be less than
convincing [19,20].
At present, the use of spirometry as a motivational tool
for smoking cessation continues to be a controversial
topic. The most recent Cochrane review of the assessment
of biomedical risks as a quit-smoking aid insists that, due
to the scarcity of high-quality analyses, no definitive con-
clusions can be reached about the effectiveness of this
approach [21]. However, it also points out that spirometry
had a significant effect in the only high-quality study, pub-
lished in 2008 by Parkes et al. [22]. This clinical trial
included 561 smokers older than 35 years who, after spiro-
metry testing, were randomized to study groups, one of
which received a summary of the results, describing their
“lung age” and comparing it with their chronological age.
After 12 months follow-up, abstinence rates confirmed by
urinary cotinine levels were significantly higher in the
intervention group (13.6% vs 6.4%, P = 0.005) and these
subjects had a higher probability of abandoning their habit
than those who did not receive this explanation (RR: 2.12;
IC95%: 1.24-3.62). Moreover, Kotz et al. published a clini-
cal trial in 2009 with the hypothesis that early detection of
COPD and the provision of information about the results
could be more effective than standard efforts to help smo-
kers to quit [23]. The study evaluated 296 smokers aged
35-70 years with COPD detected by spirometry testing,
who were randomly assigned to either confrontational
counselling for smoking cessation in which a nurse
respiratory specialist provided feedback on the results
(experimental group) or “care as usual” for smoking cessa-
tion delivered by the general practitioner. After 52 weeks
of follow-up, the intervention group achieved higher absti-
nence rates (11.2% vs 5.9%), although without reaching
statistical significance (OR: 2.02; IC95%: 0.63-6.46). These
studies appear to present contradictory results, although
congruence emerges if we analyze them in detail: the use
of spirometry in “healthy” smokers increases motivation
(and the probability of quitting smoking), while confronta-
tion with their lung function data is less effective in sub-
jects with COPD. More recently, in 2010, McClure et al.
[24] published a clinical trial with 536 smokers, recruited
from the general North American population, who were
randomized to receive a brief motivational intervention for
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Page 2 of 9smoking cessation (≈20 min), including spirometric testing
and feedback; no differences in abstinence rates were
found at 1 year of follow-up. However, in a later publica-
tion they reported that the participants with changes in
their lung function tests made greater use of quit-smoking
services and achieved an abstinence rate almost double
that of controls at 6 months (17.2% vs 8.9%, P = 0.05; OR:
2.13, IC95%: 1.04-4.5), although the effect was diluted at
12 months (16.2 vs 11.3, P = 0.26; OR: 1.52, IC95%: 0.73-
3.1) [25]. Therefore, given these other results, they con-
cluded that more research is NEEDED to determine
whether the impact of spirometry feedback differs accord-
i n gt ot h ed e t e r i o r a t i o ni nt h es m o k e r ’sp u l m o n a r y
function.
Objectives
The main objective of this study is to evaluate the effec-
tiveness in the primary care setting of a structured motiva-
tional intervention and feedback on spirometry data to
achieve smoking cessation, compared with usual clinical
practice and assessed with respect to quit rates at
12 months after the intervention.
Methods
Design
A randomized, controlled clinical trial is proposed,
enrolling current smokers with no previous history of
respiratory disease in the Primary Care Centres of the
province of Tarragona (Spain). The general design of
the study is detailed in Figure 1. This trial has been
registered with ClinicalTrial.gov (NCT01194596).
Setting and study sample
The study population will be recruited during consulta-
tions in 12 primary care practices in the province of Tar-
ragona (Spain) managed by the Catalan Health Institute,
8 of which are urban and 4 rural, serving an adult popu-
lation (aged > 18 years) of 195, 343 patients. Candidates
for participation are smokers aged 35 to 70 years who
visit a centre for any reason during regular office hours,
and who meet all inclusion criteria and none of the
exclusion criteria.
- Inclusion criteria: current smoker, with a cumulative
consumption of more than 10 packs/year.
Current smoker is defined as having smoked daily dur-
ing the past month, regardless of the quantity. Cumula-
tive consumption is defined as the daily average of
cigarettes smoked, multiplied by the number of years of
smoking, divided by 20.
- Exclusion criteria:
1) Any evidence of previous diagnosis of a respira-
tory disease,
2) Functional pulmonary testing conducted within
the previous 12 months,
3) Presence of any chronic or terminal condition
that changes the baseline parameters or complicates
the testing and analysis to be conducted during the
study period,
4) Impossibility of completing follow-up for any
reason,
5) Patient refusal to continue with the study.
Measurements
In the recruitment visit (visit 0), all potential subjects will
be advised that smokers are susceptible to COPD and that
spirometry is a simple, non-invasive test that permits the
detection of this disease at an early stage. They will then
be informed about the study and offered the possibility of
participating. Those who accept will be asked to provide
their signed informed consent. Consenting participants
will then be asked for all of the necessary information
using a structured data collection questionnaire designed
for this purpose, which will include:
￿ Affiliations and sociodemographic data.
￿ History of diseases and medications.
￿ History of respiratory symptoms.
￿ Smoking habit: current daily consumption (cigarettes/
day) and accumulated consumption (packs/year averaged
over years of smoking), nicotine dependence measured
by the Fagerström test [26], motivation to quit smoking
using the Richmond test [27] and stage of the change
process according to Prochaska and DiClemente’sm o d e l
[28].
￿ Previous quit attempts: number and therapeutic
resources used.
￿ Basic physical examination: weight, height, body
mass index, blood pressure.
￿ Expired carbon monoxide (CO) levels determined by
coximetry using the Smoke Check device (Micro Medi-
cal Limited, Rochester, Kent, England). This model
detects a CO range of 0-20 particles per million (ppm)
with a sensitivity of 1 ppm.
￿ Spirometry and a bronchodilator test, using an ultra-
sound pneumotacograph Datospir-600 (SIBELMED, S.A.).
Allocation of study groups
All patients will be scheduled for assessment of their
lung function, using spirometry, at their primary care
centre. The quality of testing will be ensured by a three-
tiered system of quality control:
1) Standardization of pulmonary function testing. Only
tests that meet the quality recommendations and criteria
of the American Thoracic Society-European Respiratory
Society [29,30] will be accepted as valid:
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selection of the best values of forced vital capacity
(FVC), forced expiratory volume in 1 s (FEV1), and
FEV1/FVC ratio;
b )V a r i a b i l i t yb e t w e e nt h e s em e a s u r e sm u s tb el e s st h a n
5%, exhalation time greater than 6 s, and the attempt
must be properly initiated, with a rapid increase;
c) Airflow-limitation reversibility will be determined
and considered positive if it is greater than 12% and
improvement in FEV1 > 200 ml, observed after the
administration of 400 micrograms of salbutamol
inhaled with a valve-holding chamber (spacer).
2) Technical considerations. To facilitate access, all
testing will be conducted at each participating centre by
technicians selected from the nursing staff, who must be
able to show specifically accredited training from the
Health Research Institute of Catalonia.
3) Centralized supervision. All testing will be sent to one
reference observer who will be responsible for centralized
quality control and will interpret the results by following
an automated process using a previously validated and
registered computer program (ESPIRO) [31]. Finally, a
clinical report will be generated and analyses will be con-
sidered normal if they meet the following criteria:
- FEV1 ≥ 80% of the theoretical reference value
- FVC ≥ 80% of the theoretical reference value
- FEV1/FVC ≥ 0.7
Subjects with test results within normal range will be
allocated to receive or not the proposed intervention.
The assignment sequence will be centralized at the
Research Support Unit of the IDIAP Jordi Gol in Tarra-
gona and will be blinded and performed consecutively,
following a simple, numerical relationship randomiza-
tion issued for this purpose. Due to the nature of the
intervention it is impossible for the patient or the
researcher to be blinded to the assignment.
Description of the intervention and control group
Within one month of their random assignment, all parti-
cipants will be contacted to schedule their intervention
Figure 1 Diagram of the ESPITAP study: process of selection, randomization and follow-up of subjects included in the study.
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tion and counselling on smoking cessation from their
physician (Table 1). Control group subjects will have a
brief visit (5-10 min) in the format that is usually recom-
mended for primary care professionals [32]: a clear, firm,
personalized proposition recommending that they quit
smoking, in an empathic and respectful context.
Patients assigned to the intervention group will receive a
written spirometry report and a detailed, structured expla-
nation of the content during a personalized visit of 15 to
20 min, using a motivational interview approach. Research-
ers at the participating centres will come to a consensus on
the comments about spirometry to be delivered, and these
will focus on a standardized description of FEV1, FVC,
forced expiratory flow between 25% and 75% of the FVC
(FEF25-75%) and peak expiratory flow (PEF) values and
their interpretation in terms of their theoretical value. In
addition, they will inform subjects about the lung age index
(defined as the average age of a non-smoker with the same
FEV1 value as the subject in question) [33], comparing this
value with the chronological individual age to illustrate the
lung damage suffered as a consequence of smoking. In
practice, the lung age is automatically generated by config-
uring the spirometer. The Fletcher-Peto graph [18] will be
used to depict how the loss of lung function that occurs
with age can be accelerated in smokers and how quitting
smoking normalizes the pace of pulmonary deterioration,
even though the lost capacity cannot be recovered.
With respect to patients with changes in their test values
(FEV1 and/or FVC < 80% of the theoretical value and/or
FEV1/FVC < 0.7), all will be informed about them and
also referred to their physician for evaluation, verification
of test results, and clinical follow-up according to the stan-
dard practice at each centre.
Independent of their group assignment, all participants
who show an interest in quitting smoking will be offered
a treatment option in the smoking cessation program
that forms part of the usual activities of each centre.
Both physicians and nurses at the participating centres
will receive support and at least 8 h of specific training
on spirometry and motivational interview techniques,
applied to smoking addiction, which will be accredited
by the Catalan Health Institute.
Follow-up period
All subjects will be evaluated during a telephone fol-
low-up at 6 months post-intervention (visit 2) to deter-
mine whether there has been any change in their
smoking status and to record new data about tobacco
consumption or, where applicable, to record quit date.
Finally, at 12 months after inclusion in the study, they
will be scheduled for their final study visit (visit 3),
which will take place at the corresponding centre. At
this last visit, new data will be collected on each sub-
ject’s smoking habit (current consumption, depen-
dence, motivation and stage in the change process) or,
where applicable, quit date. Patients who claim to have
quit smoking will undergo a breath test to measure
expired CO.
Main outcome variables
The primary variable will be prolonged abstinence from
smoking, and a secondary variable occasional abstinence
(point prevalent abstinence), both of which will be vali-
dated using confirmation by coximetry at 12 months post-
intervention. The cut-off point to confirm abstinence will
be 10 ppm, since lower values indicate a non-smoker and
higher values reflect having smoked within the preceding
12 to 24 h [34].
The criterion to establish abstinence takes into account
the Society for Research on Nicotine and Tobacco
recommendations and definitions [35]:
- Continuous abstinence refers to sustained abstinence
between the point of intervention and a follow-up point.
- Prolonged abstinence refers to sustained abstinence
from an initial “grace period” until a follow-up point. The
“grace period” is understood as the time immediately
after a definite quit date or intervention during which
Table 1 Smoking cessation counseling protocol
Smoking cessation counseling protocol
Control group counseling: brief intervention
“As your doctor, I recommend that you quit smoking, although the decision is yours alone. I know that it is difficult to make a decision right now, but we
have a number of resources that can help you quit smoking and I know that if you decide to quit in the future you will be able to do that. Remember
that you can always count on us to help.”
Intervention group counseling: detailed discussion of spirometry
“Tobacco is harmful to your health. Smoking can produce various diseases such as, for example, those that affect your lungs. Some smokers end up
getting a chronic pulmonary disease that is commonly called chronic bronchitis. To diagnose that disease, we use a test called spirometry that measures
lung capacity. This is the test I gave you. In your case, the results indicate that you do not have this disease now, but some of the data suggest that
tobacco is causing some changes in your lungs.
These values - FVC, FEV1, FEV25-75 - indicate that you have lost part of the capacity you had to exhale air, specifically, you have lost about..........%.
Tobacco also accelerates the usual aging of the lungs. This effect can be seen in this “lung age” value, which is....... years.
In summary, although at this time, given your results, we would not say you are sick, looking at the rest of the data, the best thing for your health is to
stop smoking as soon as possible.”
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most studies, the recommendation is that this period not
exceed 2 to 4 weeks.
- Point prevalence abstinence refers to abstinence dur-
ing a time window immediately before the follow-up
point (usually 7 days).
- Failure to quit refers to a smoking relapse (of any type)
lasting 7 consecutive days (defined by the U.S. National
Heart, Lung, Blood Institute).
In general, continuous abstinence is accepted as the gold
standard, but this is a very rigorous measure; therefore,
prolonged abstinence is preferred because it allows inclu-
sion in the analysis of subjects who achieve a sustained
abstinence after a transitional “grace period” and whose
effort would otherwise be considered failure.
Sample size calculation
To achieve the study’s main objective, sample size is cal-
culated in accordance with the following parameters:
identification of a difference equal to or greater than 8%
between the intervention group and control group with
regard to abandonment or reduction of tobacco use, a
10% abandonment or reduction in the control group, an
a l p h ar i s ko f0 . 0 5 ,a n dab e t ar i s ko f0 . 2 0i nat w o - t a i l e d
contrast. Consequently, for this study it will be necessary
to randomize a total of 590 subjects (295 in each group).
Taking into account a withdrawal rate of 10%, the total
sample size will be 649 subjects.
At each of the 12 participating centres, it should be
reasonable to expect the associated researchers to
include about 50 participants in this study (25 in each
group).
Analysis strategy
Data will be drawn from a centralized database and
grouped so that those responsible for analysis will be
blinded to participants’ study group assignment.
The effectiveness of randomization to assess the com-
parability and consistency of intervention and control
groups will be checked in terms of the similarity of the
distribution of the variables of interest at baseline. Losses
to follow-up in each group will be quantified and
assessed to rule out a possible selection bias.
All analysis will be conducted on the principle of
intention to treat. Losses to follow-up will be quantified
in each group and assessed to determine whether any
possible bias was introduced to the results. A “worst-
case analysis” strategy will be used, assuming that the
expected response occurred in the control group
patients lost to follow-up and did not occur in the inter-
vention group. Using this assumption, the data will be
reanalyzed and the magnitude of the observed difference
between the initial results and the “worst-case” estimates
will be assessed. This approach is valid except in the
unlikely case that losses to follow-up exceed 20%.
Standard statistical tests will be used for both quanti-
tative and qualitative variables described (e.g. means,
standard deviations, medians, proportions).
Continuous abstinence, prolonged abstinence rates, and
point prevalence abstinence at 6 and 12 months after
intervention will be calculated, along with Cox analysis of
survival (abstinence). In cases of failure to quit, consump-
tion data, motivation, and number of attempts to quit
smoking during follow-up will be collected and compared
with those who achieved a level of abstinence.
The results will be presented using both relative and
absolute measures: relative risk (RR) and relative risk
reduction (RRR) and absolute risk reduction (ARR) and
the number needed to treat (NNT), or number of smo-
kers who must try to quit to succeed in getting one to
remain abstinent. All measures will be expressed with
their respective confidence intervals (CI) of 95%.
To assess the influence of studied parameters on the
rates of abstinence and failure, logistic regression will be
used, calculating odds ratios (OR) and 95% CI. As part of
the statistical analysis, multiple logistic regression models
will be fitted to adjust for potential confounding covariates
of the primary outcome (age, sex, educational level, num-
ber of previous quit attempts, nicotine dependence, moti-
vation to quit smoking, comorbidity, etc.) [36,37].
Statistical analysis will be performed with SPSS ver-
sion 14.0. The tests will be considered significant when
P < 0.05.
Ethical aspects
The protocol, informed consent form, participant infor-
mation sheet and any applicable documents were sub-
mitted to an appropriate Ethics Committee (EC) and
Regulatory Authority of Institute of Primary Care
Research (IDIAP) Jordi Gol for written approval and the
study protocol was approved by the registration number
ID 4R07/040. All substantial amendments to the original
approved documents will also be sent to an appropriate
EC and regulatory authority for written approval.
Investigators will ensure that this study is conducted
in accordance with the principles of the Declaration of
Helsinki and ICH Guidelines for Good Clinical Practice,
and in full conformity with relevant regulations.
All participants will be informed of the study, its
objectives and activities related to their participation:
number and schedule of visits, diagnostic test, results
information, etc.
Written information will be given and they will be
asked to sign a consent form.
Patients with any previously undiagnosed impairment
will be referred to the appropriate diagnostic and thera-
peutic unit, which will be responsible for integrating
information and providing the best diagnostic and thera-
peutic option.
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is maintained. Participants will be identified only by a PID
number on the CRF and any electronic database. All docu-
ments will be stored securely and only accessible by trial
staff and authorized personnel. The study will comply
with the Data Protection Legislation requirements for
anonymization of data.
Discussion
The etiological relationship between COPD and smoking
is no longer subject to discussion due to the available epi-
demiological, morphological and genetic evidence. There
is no room for doubt that quitting smoking is the best way
to reduce the risk of COPD, and is the most efficient inter-
vention and the only effective treatment to improve survi-
val [1]. However, smoking requires an intensive approach
that is not always viable under the actual conditions of
everyday clinical practice, which is often consumed with
massive numbers of patient visits. Therefore, it is of funda-
mental importance to have evidence of ways to maximize
these interventions.
The present study will evaluate, under nearly actual con-
ditions of primary care, the efficacy of a quit-smoking
strategy directed at individuals at any of the stages of
change. The theoretical framework used is to provide per-
sonalized motivational information about the effects of
smoking, with the goal of accelerating a change in habit.
This idea is not new and was the subject of a recent
Cochrane review [21]. Although certain prestigious
authors and institutions [8,20] have raised questions about
the usefulness of this type of strategy, recent data allow us
to assume that some patients can benefit from it [22,25].
One plausible explanation of this apparent contradiction is
that if an intervention is to succeed there must be some
change in testing results and an adequate presentation of
them [37]. If this were the case, being able to prove a
change should have implications for clinical practice.
Primary care, with its population context and continuity
of care throughout a patient’s life, has a core role in any
strategy to break a smoking habit. One of the main tasks
of first-line care professionals is to increase patient moti-
vation to quit smoking, and on many occasions it must be
attempted in young, healthy smokers that have come to
the doctor for some other reason. The ESPITAP study
presents a pragmatic design that reflects these conditions,
attempting to establish an intervention that can be easily
applied in clinical practice. For that reason, it takes into
account the usual attention these subjects receive and is
intended to be incorporated into the daily clinical activity
of the researchers.
The designed intervention is less intense than the one
described in other studies that have taken a motivational
approach, and this is not of marginal importance: a direct
dose-response association has been demonstrated between
intensity, success of the intervention, and abstinence rates
[21]. Although one could then assume that another more
intensive approach would be more appropriate, at the
same time this would distance us from the conditions of
daily practice that the study attempts to reflect.
A primary strength of the study is its rigorous metho-
dology that involves a large number of health profes-
sionals and patients, which will strengthen the validity
of the results. Although it will be difficult to control the
extent to which the personal skills of the researchers
might influence the success of the intervention, its for-
mat, content, and duration will be standardized in an
effort to minimize this potential confounder.
Conclusions
In conclusion, the use of spirometry as a motivational
instrument for smoking cessation continues to be a con-
troversial topic. Although the available studies seem to
highlight the efficacy of this intervention, there is insuffi-
cient evidence to establish definitive conclusions about
its effectiveness. The results of the present study could
contribute to clarify these and other questions of practi-
cal utility for primary care professionals.
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